Navigation Links
VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results
Date:9/8/2009

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, plans to announce the results from the EQUIP and CONQUER Qnexa(TM) phase 3 obesity clinical trials on September 9th prior to market open. The announcement will be followed by a webcast and conference call at 8:00 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-967-7185

International callers: 1-719-325-2352

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations: The Trout Group
    Timothy E. Morris                              Brian Korb
    Chief Financial Officer                        646-378-2923
    650-934-5200
                               Media Relations:    Pure Communications, Inc.
                                                   Sheryl Seapy
                                                   949-608-0841

'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VIVUS Reports Second Quarter 2009 Financial Results
2. VIVUS Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
3. WellPoint Announces Appearance at Upcoming Conference
4. Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference
5. NeoStem to Present at Rodman & Renshaws 11th Annual Healthcare Conference
6. BioCryst Executives to Present at Two Investor Conferences
7. SYGNIS to Present at the 11th Rodman & Renshaw Annual Global Investment Conference
8. NHP to Present at the BMO Capital Markets 2009 North American Real Estate Conference
9. Amgen to Present at the Baird Healthcare Conference
10. Gentiva(R) Health Services to Present at the Robert W. Baird & Co. Health Care Conference
11. Newly Formed American Society for Nanomedicine (ASNM) to Hold First Conference (www.amsocnanomed.org)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: